TICKERNERD
Menu
NAMSNAMSHealthcare · Biotechnology

NAMS Stock Forecast: NewAmsterdam Pharma Co. NV Price Predictions for 2026-2027

Last close, 14 Oct 2026
$20
−0.89% on the day

The 16 Wall Street analysts covering NewAmsterdam Pharma Co. NV hold a median 12-month price target of $50 — +150.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.4B
Ticker Nerd rank
39 / 100
Median analyst target
$50
Analysts covering
16
Revenue$3.7M−80.7% y/y
Operating income−$64.9M
Net income−$64.1M
Free cash flow−$39.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.6%
1M
−10.5%
YTD
−43.0%
1Y
−47.1%
From 52W high
−51.7%
From 52W low
0.0%
$20
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NAMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NewAmsterdam Pharma Co. NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
72
Value
71
Volatility
64
Quality
54
Revisions
49
Momentum
40
Issuance
35
Size
33
Growth
18

Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NAMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26NAMSHigh $59Median $50Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $38Median $50High $59

The green dot is the last close — the median target sits +150.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
5 Oct 2026RBC CapitalMaintainsOutperform$50 → $42
8 Sept 2026HC Wainwright & Co.ReiteratesBuy—
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$52
6 Aug 2026RBC CapitalMaintainsOutperform$51 → $50
6 Aug 2026RBC CapitalMaintainsOutperform—
30 June 2026RBC CapitalMaintainsOutperform$47 → $51
30 June 2026RBC CapitalMaintainsOutperform—
19 Feb 2026GuggenheimMaintainsBuy—
18 Feb 2026NeedhamMaintainsBuy—
21 Jan 2026RBC CapitalMaintainsOutperform—
16 Dec 2025StifelMaintainsBuy—
2 Dec 2025Goldman SachsMaintainsNeutral—
6 Nov 2025RBC CapitalMaintainsOutperform—
5 Nov 2025NeedhamMaintainsBuy—
20 Oct 2025HC Wainwright & Co.AssumesBuy$52
17 Oct 2025CitigroupMaintainsBuy—
25 Aug 2025Wells FargoInitiatesOverweight—
7 Aug 2025RBC CapitalMaintainsOutperform—
17 July 2025Goldman SachsInitiatesNeutral—
17 June 2025CitigroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAMS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NAMS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, NewAmsterdam Pharma Co. NV returned −47.1% against +18.7% for the S&P 500, dividends included.

NAMS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26NAMSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NAMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

NewAmsterdam Pharma Co. NV (NAMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.3×

Cheaper than 94% of US stocks

Price / sales
331.5×

Cheaper than 2% of US stocks

Price / book
3.8×

Cheaper than 24% of US stocks

EV / EBITDA
−7.3×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−80.7%

Higher than 3% of US stocks

Earnings growth (YoY)
−80.7%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−1752.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.8%

Higher than 25% of US stocks

Return on assets
−20.1%

Higher than 19% of US stocks

Dividend yield
3.3%

Higher than 86% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NewAmsterdam Pharma Co. NV (NAMS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NewAmsterdam Pharma Co. NV has a market value of $2.4B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $7.1M. The latest quarter shrank 80.7% year on year.

  • Net income over the same four quarters: −$259.5M, a −3644.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$143.7M.

  • Shares outstanding: 117.7M.

  • Trailing P/E: −11.3×; forward P/E: −13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 3.26%, paying out 0% of earnings.

  • NewAmsterdam Pharma Co. NV employs 100 people — $71K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

NAMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NAMSNewAmsterdam Pharma Co. NV$2.4B
39
MBXMBX Biosciences, Inc.$2.3B
36
ADMAADMA Biologics, Inc.$2.3B
49
NRIXNurix Therapeutics, Inc.$2.2B
93
AUPHAurinia Pharmaceuticals, Inc.$2.2B
93
CLDXCelldex Therapeutics, Inc.$2.2B
27
BEAMBeam Therapeutics, Inc.$2.5B
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NewAmsterdam Pharma Co. NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NAMS news & analysis

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

NewAmsterdam Pharma's Compensation Committee approved the grant of inducement share options covering 71,800 ordinary shares to seven non-executive new hires, awarded as an inducement material to their acceptance of employment under the company's 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — NAMS watchers would note that the company is bringing on new staff and tying their recruitment to share-based incentives under Nasdaq rules, which may signal ongoing hiring and talent expansion.

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease

GlobeNewsWire · 29 Sept 2026neutral

NewAmsterdam Pharma announced it has dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not yet show noticeable memory or functional symptoms. The study will assess changes in blood-based Alzheimer's biomarkers, including p-tau 217, along with cognitive and functional measures.

Why it matters — This marks a new clinical indication for obicetrapib beyond cardiovascular disease, which NAMS watchers would follow as it expands the company's pipeline into early-stage Alzheimer's disease.

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

GlobeNewsWire · 21 Sept 2026positive

NewAmsterdam Pharma and Menarini Group received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination). This first-in-class approval was supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials showing significant LDL-C reductions with a favorable tolerability profile.

Why it matters — European Commission approval of its lead products marks a major regulatory milestone for NewAmsterdam Pharma, potentially expanding its commercial opportunity.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Sept 2026neutral

NewAmsterdam Pharma's Compensation Committee approved inducement share options covering a total of 38,900 ordinary shares for five new non-executive hires, plus 14,000 shares for new Vice President, Controller and principal accounting officer Robert Gunning. The grants were made under the company's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as inducements material to the employees' acceptance of employment.

Why it matters — The inducement grants signal new hires joining the company, including a new principal accounting officer, which NAMS watchers would note as routine corporate governance and staffing activity.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

GlobeNewsWire · 2 Sept 2026neutral

NewAmsterdam Pharma Company N.V. announced on September 2, 2026, that it will participate in upcoming investor conferences during September. The announcement was issued from the company's offices in Naarden, The Netherlands, and Miami.

Why it matters — NAMS watchers would care because the company's scheduled participation at investor conferences offers opportunities for management to present updates and engage with the investment community.

FAQ

Frequently asked questions about NAMS stock

What is the NAMS stock price forecast for 2026-2027?

The 16 Wall Street analysts covering NewAmsterdam Pharma Co. NV have a median 12-month price target of $50, with estimates ranging from $38 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAMS stock a buy right now?

Of the 16 analysts covering NewAmsterdam Pharma Co. NV, 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NewAmsterdam Pharma Co. NV 39 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAMS?

As at 13 Oct 2026, NewAmsterdam Pharma Co. NV ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).

Will NAMS stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +150.7% from the last close, and Ticker Nerd's factor model ranks NewAmsterdam Pharma Co. NV 39 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAMS stock forecast for 2030?

No analyst covering NewAmsterdam Pharma Co. NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $59 over the next 12 months.

How has NAMS stock performed over the past year?

NewAmsterdam Pharma Co. NV returned -47.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NewAmsterdam Pharma Co. NV do?

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated.

What is the latest news on NAMS?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". NewAmsterdam Pharma's Compensation Committee approved the grant of inducement share options covering 71,800 ordinary shares to seven non-executive new hires, awarded as an inducement material to their acceptance of employment under the company's 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About NewAmsterdam Pharma Co. NV.

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. The company’s lead program centers on obicetrapib, a low-dose oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to help lower LDL cholesterol in cardiovascular settings. NewAmsterdam Pharma also works on broader applications for cardiometabolic care, reflecting its emphasis on non-statin medicine and patient-friendly treatment options. Headquartered in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. serves the biotechnology and pharmaceuticals market by advancing drug candidates aimed at addressing unmet needs in long-term cardiovascular risk management.

CEO Dr. Michael Harvey Davidson FACC, Facp., M.D. · 100 employees · Netherlands · https://www.newamsterdampharma.com